Page 139 of 154: studies 1,381 to 1,390 of 1,534, newest first. Back to the ketamine for depression overview
New England Journal of Medicine May 22, 2019 Jean Kim, Tiffany R. Farchione, Andrew Potter et al.
Esketamine for Treatment-Resistant Depression The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset...
American Journal of Psychiatry May 21, 2019 Vanina Popova, Ella Daly, Madhukar H. Trivedi et al. 879 citations
OBJECTIVE: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active...
May 14, 2019
Ketamine has emerged as the prototypical rapid-acting antidepressant. Early efficacy studies showed a high rate of response (64% to 71%) to a single dose of ketamine among individuals with treatment-resistant depression. Later clinical reports of the effectiveness of ketamine in clinical samples demonstrated a response rate of approximately 50%. This discrepancy between efficacy and...
Indian Journal of Psychiatry May 1, 2019 Amit Jagtiani, H. Khurana, N. Malhotra 15 citations
Background: It is well known that depression improves faster with electroconvulsive treatment (ECT) than with antidepressant medications. N-methyl-D-aspartate-receptor antagonists (ketamine) have been shown to have rapid antidepressant effects when given as an intravenous infusion. Faster recovery with ECT is likely when used with ketamine as anesthetic. Aim: The aim of the study is to compare...
Journal of Affective Disorders May 1, 2019 Wei Zheng, Xiaohong Li, Xiao-Min Zhu et al. 57 citations
BACKGROUND Adjunctive ketamine with electroconvulsive therapy (ECT) has been investigated for treating major depressive disorder (MDD), but the findings have been inconsistent. AIM This is an updated meta-analysis of the efficacy and safety of ketamine augmentation of ECT in the treatment of MDD. METHODS Randomized controlled trials (RCTs) reporting on the efficacy and safety of ketamine and...
The Journal of Clinical Psychiatry April 15, 2019 Joshua D. Rosenblat, André F. Carvalho, Madeline Li et al. 111 citations
OBJECTIVE: Intravenous (IV) ketamine has rapid and robust antidepressant effects; however, poor accessibility of the IV route often limits its use. Numerous alternative routes of administration are being investigated. Oral ketamine is particularly appealing for its ease of use with the potential for high accessibility. The objective of the current systematic review, in accordance with PRISMA,...
Advanced Biomedical Research April 10, 2019 G. Kheirabadi, M. Vafaie, Dorna Kheirabadi et al.
Background: Achieving a rapid onset and durable methods of treatment for major depressive disorders is an issue pursuing in psychiatry. This study was designed to assess the therapeutic efficacy of intravenous (IV) ketamine injection in controlling depressive symptoms in comparison with electroconvulsive therapy (ECT) in major depressed disordered patients. Materials and Methods: Thirty-two...
Cutting Edge Psychiatry in Practice March 31, 2019 James Stone
There has been considerable interest in the potential of ketamine as a novel antidepressant with a unique mechanism of action. In a number of small trials, ketamine has been shown to lead to reductions in depressive symptoms within hours of administration in patients with symptoms that are otherwise refractory to treatment, with the antidepressant response lasting for days. Although the...
American Journal of Psychiatry March 29, 2019 J. Phillips, S. Norris, J. Talbot et al. 416 citations
OBJECTIVE Subanesthetic ketamine doses have been shown to have rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was to evaluate the antidepressant effects of a single ketamine infusion, a series of repeated ketamine infusions, and prolongation of response with maintenance...
Journal of Clinical Psychopharmacology March 1, 2019 Kelly A. Bryant, Murat Altinay, Nora Finnegan et al.
Abstract Purpose There is an immediate need for more sustainable, effective therapies for treatment-resistant depression in patients who do not respond to traditional psychopharmacology. The aim of this study was to determine the efficacy and safety of intravenous ketamine infusions on the elderly population by using a case series of 6 geriatric patients with treatment-resistant depression....